2023 Mid-Year Update

The Directors of Inizio are pleased to present a mid-year update for 2023.

Inizio is a product commercialization platform for pharma and biopharma clients, offering a complete suite of marketing, medical, advisory, communications and patient-engagement services. Our in-house capabilities and knowledge provide our clients with access to best-in-class expertise when needed along the clinical development to commercialisation journey.

Trading performance from our businesses continues to be strong reflecting solid market fundamentals and the critical nature of the services we offer. Revenues for the first half of 2023 have grown double digit, driven by a combination of existing and new clients and supported by continued growth in the pharmaceutical and biotech sector.

At a strategic level, by purposefully combining to create Inizio, we have built the widest and deepest range of services of any commercialization partner to navigate every pivotal moment across the full value chain of the commercialization lifecycle, across all 14 therapy areas. Our scaled commercialization platform connects best-in-class capabilities, across 11,700 experts in 50 countries, as our clients activate from early-stage development, through commercialization and launch on their journey to the patient. We have partnered on 1,100 assets in the past 2 years with a large proportion of those in the fastest growing therapeutic areas. We are also a product launch powerhouse, helping our clients successfully plan and execute launch activity – in the past 2 years Inizio has supported 50% of all US product launches, many of which are projected to be market blockbusters in terms of commercial performance. Unlocking this value from our scaled platform for our clients is a strategic imperative, and we remain focussed on the areas of great client need, value and innovation.

The Group continues to trade in line with and remains comfortably compliant with the terms of its debt facilities. We are well placed to build upon the success of the first half of the year to deliver longer-term value creation.